Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk189254. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [11C]Gsk-189254 SCHEMBL13217225 | 1.00 | HRH3 (1.00) | HRH3HRH1 | |
| Gsk189254 SCHEMBL29769888 | 1.00 | HRH3 (1.00) | HRH3HRH1 | |
| Gsk189254 SCHEMBL13788699 | 1.00 | HRH3 (1.00) | HRH3HRH1 | |
| Gsk189254 SCHEMBL964054 | 0.99 | HRH3 (0.98) | HRH3HRH1 | |
| SCHEMBL3100997 | 0.98 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL5452228 | 0.93 | HRH3 (0.86) | HRH3HRH1 | |
| Gsk189254 SCHEMBL17639965 | 0.92 | HRH3 (0.84) | HRH3HRH1 | |
| SCHEMBL3081489 | 0.91 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL3089493 | 0.90 | HRH3 (0.82) | HRH3HRH1 | |
| SCHEMBL3094776 | 0.90 | HRH3 (0.82) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBVIE INC (US) | 2016-03-31 | — | — | US | claimed |
| EP-2186516-B1 | Novel benzazepine derivative | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | claimed |
| EP-2424528-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| US-20110020447-A1 | NOVEL DOSAGE FORM | GLAXO GROUP LIMITED (GB) | 2011-01-27 | — | — | US | claimed |
| WO-2010129242-A2 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | claimed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| EP-2186516-A1 | Novel benzazepine derivative | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | claimed |
| US-7696193-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-04-13 | — | — | US | claimed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | claimed |
| US-20080159958-A1 | DETERMINATION OF HISTAMINE-3 BIOACTIVITY | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | disclosed |
| US-20070059230-A1 | Process | GLAXO GROUP LIMITED | 2007-03-15 | — | — | US | disclosed |
| US-20070059230-A1 | Process | GLAXO GROUP LIMITED | 2007-03-15 | — | — | US | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | HRH3 2876/4885HRH1 1963/4885 |
| US-20160089378-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885 |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | HRH3 49/4885HRH1 124/4885 |
| US-20100273778-A1 | TREATMENT OF OSTEOARTHRITIS PAIN | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | HRH3 211/4885HRH1 286/4885 |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885HRH1 947/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | HRH3 3968/4885HRH1 3582/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | HRH3 243/4885HRH1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.